Immunovant (IMVT) Rises 14.0% Following $550 Million Equity Raise Backed by Roivant for IMVT-1402 - Is the Bullish Outlook Still Valid?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 15 2025
0mins
Source: Yahoo Finance
Equity Offering Details: Immunovant raised US$550.20 million through a follow-on equity offering, issuing 26.2 million shares at US$21.00 each, primarily to fund the development of its lead candidate IMVT-1402 for Graves’ disease and other autoimmune conditions.
Roivant Sciences' Commitment: Controlling shareholder Roivant Sciences invested approximately US$349.90 million in the offering, which strengthens Immunovant's financial position as it prepares for pivotal clinical trials and a potential product launch.
Shift in Risk Profile: The capital raise alleviates immediate cash flow concerns but shifts the focus to execution risks related to clinical trials and ongoing losses, which exceed US$400 million annually.
Valuation Insights: Analysts suggest Immunovant's share price may be overvalued, with estimates varying widely; some believe the stock could be worth up to 49% more than its current price, highlighting the need for careful evaluation of investment risks and opportunities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ROIV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ROIV
Wall Street analysts forecast ROIV stock price to fall
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 27.760
Low
22.00
Averages
27.63
High
33.00
Current: 27.760
Low
22.00
Averages
27.63
High
33.00
About ROIV
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Perceptive Advisors Increases Stake in Celcuity
- Stake Increase: Perceptive Advisors purchased an additional 203,881 shares of Celcuity in Q4 2026, with an estimated transaction value of $16.76 million, indicating strong confidence in the company's future growth potential.
- Ownership Proportion Rise: Following this purchase, Perceptive Advisors' stake in Celcuity increased to 5.62%, highlighting its significance within the investment portfolio and further drawing market attention to Celcuity.
- Market Performance: As of February 17, 2026, Celcuity shares were priced at $107.32, reflecting a staggering 700% increase over the past year, underscoring strong market anticipation for its drug development.
- FDA Review Progress: Celcuity's new drug application for gedatolisib has received Priority Review from the FDA, with a decision expected by July 17, 2026, a critical timeline that could significantly impact its future market performance.
See More
Roivant Sciences (ROIV.US) Officer Plans to Sell $44.03 Million in Common Stock via Form 144
Stock Sale Announcement: Officer Frank Torti plans to sell 1.6 million shares of Roivant Sciences common stock on February 20, with a total market value of approximately $44.03 million.
Shareholding Reduction: Frank Torti has reduced his shareholding in Roivant Sciences by 1.4 million shares since February 19, 2026, with a total value of around $38.39 million.
See More
David Einhorn's Concerns on AI Overvaluation Impacting Stock Picks
- Investment Strategy Shift: David Einhorn invested tens of millions in Q4 2025 to increase stakes in Graphic Packaging and Capri Holdings by over 70%, reflecting his concerns about AI-driven market overvaluation and indicating a strategic pivot away from big tech.
- Stock Performance Volatility: Despite Graphic Packaging's shares dropping about 23% in Q4 2025 and over 44% for the year, Wall Street analysts remain optimistic, with an average price target suggesting more than 35% upside, indicating expectations for a rebound in the stock.
- Healthcare Investments: Einhorn more than doubled his position in Acadia Healthcare to over $58 million, despite a 43% plunge in Q4; however, analysts maintain a buy rating with a price target suggesting over 16% upside in the next 12 months, reflecting confidence in its recovery.
- Cautious on Tech Stocks: While expressing concerns about tech valuations, Einhorn established a $35 million stake in Global Payments, which fell 31% in 2025 but rebounded nearly 5% in 2026, with analysts' price targets implying over 25% upside, suggesting market optimism for its future performance.
See More
Citi and H.C. Wainwright Raise Roivant Sciences Price Targets Following Positive Drug Data
- Price Target Increases: Citi raised Roivant Sciences' price target from $26 to $35 while maintaining a Buy rating, primarily based on positive Phase 2 data for brepocitinib in cutaneous sarcoidosis, indicating strong growth potential for the drug.
- Impressive Data Performance: H.C. Wainwright also increased Roivant's price target from $26 to $33, emphasizing the impressive Phase 2 data and incorporating this indication into their valuation model, reflecting growing market confidence in the drug.
- Bank Rating Changes: Prior to this, Bank of America raised Roivant's price target from $22 to $26 with a Neutral rating, noting that FQ3 2026 results were in line with expectations and highlighting the positive topline results for brepocitinib.
- Optimistic Market Outlook: With analysts raising sales forecasts for brepocitinib, Roivant Sciences' market outlook is generally positive, showcasing the company's potential and investment value in the biopharmaceutical sector.
See More
Roivant Sciences (ROIV.US) Officer Plans to Sell $5.3 Million in Common Stock via Form 144
Stock Sale Announcement: Officer Venker Eric plans to sell 200,000 shares of its common stock on February 13, with an estimated market value of around $5.3 million.
Reduction in Shareholding: Venker Eric has decreased his shareholding in Roivant Sciences by 682,050 shares since November 20, 2025, totaling an approximate value of $14.88 million.
See More
Top Performing Large-Cap Stocks Last Week
- Lumentum Earnings Beat: Lumentum Holdings Inc. surged 36.02% this week after reporting second-quarter results that exceeded expectations and providing third-quarter guidance above analyst estimates, thereby boosting investor confidence and significantly driving up the stock price.
- Transportation Stocks Rally: Saia, Inc. jumped 23.07% this week, benefiting from declining oil prices, which led to a strong performance across the transportation sector, indicating optimistic market expectations for transportation demand that could enhance future earnings.
- Westlake Stock Increase: Westlake Corporation saw a 19.27% rise in its stock price this week, reflecting positive market sentiment regarding its business outlook, particularly in the context of declining raw material costs that may improve profitability.
- Market Recovery: The strong performance of these stocks indicates a growing investor confidence in economic recovery, especially amid falling oil prices, which could further drive growth in related industries.
See More
Perceptive Advisors Increases Stake in Celcuity
- Stake Increase: Perceptive Advisors purchased an additional 203,881 shares of Celcuity in Q4 2026, with an estimated transaction value of $16.76 million, indicating strong confidence in the company's future growth potential.
- Ownership Proportion Rise: Following this purchase, Perceptive Advisors' stake in Celcuity increased to 5.62%, highlighting its significance within the investment portfolio and further drawing market attention to Celcuity.
- Market Performance: As of February 17, 2026, Celcuity shares were priced at $107.32, reflecting a staggering 700% increase over the past year, underscoring strong market anticipation for its drug development.
- FDA Review Progress: Celcuity's new drug application for gedatolisib has received Priority Review from the FDA, with a decision expected by July 17, 2026, a critical timeline that could significantly impact its future market performance.
See More
Roivant Sciences (ROIV.US) Officer Plans to Sell $44.03 Million in Common Stock via Form 144
Stock Sale Announcement: Officer Frank Torti plans to sell 1.6 million shares of Roivant Sciences common stock on February 20, with a total market value of approximately $44.03 million.
Shareholding Reduction: Frank Torti has reduced his shareholding in Roivant Sciences by 1.4 million shares since February 19, 2026, with a total value of around $38.39 million.
See More
David Einhorn's Concerns on AI Overvaluation Impacting Stock Picks
- Investment Strategy Shift: David Einhorn invested tens of millions in Q4 2025 to increase stakes in Graphic Packaging and Capri Holdings by over 70%, reflecting his concerns about AI-driven market overvaluation and indicating a strategic pivot away from big tech.
- Stock Performance Volatility: Despite Graphic Packaging's shares dropping about 23% in Q4 2025 and over 44% for the year, Wall Street analysts remain optimistic, with an average price target suggesting more than 35% upside, indicating expectations for a rebound in the stock.
- Healthcare Investments: Einhorn more than doubled his position in Acadia Healthcare to over $58 million, despite a 43% plunge in Q4; however, analysts maintain a buy rating with a price target suggesting over 16% upside in the next 12 months, reflecting confidence in its recovery.
- Cautious on Tech Stocks: While expressing concerns about tech valuations, Einhorn established a $35 million stake in Global Payments, which fell 31% in 2025 but rebounded nearly 5% in 2026, with analysts' price targets implying over 25% upside, suggesting market optimism for its future performance.
See More
Citi and H.C. Wainwright Raise Roivant Sciences Price Targets Following Positive Drug Data
- Price Target Increases: Citi raised Roivant Sciences' price target from $26 to $35 while maintaining a Buy rating, primarily based on positive Phase 2 data for brepocitinib in cutaneous sarcoidosis, indicating strong growth potential for the drug.
- Impressive Data Performance: H.C. Wainwright also increased Roivant's price target from $26 to $33, emphasizing the impressive Phase 2 data and incorporating this indication into their valuation model, reflecting growing market confidence in the drug.
- Bank Rating Changes: Prior to this, Bank of America raised Roivant's price target from $22 to $26 with a Neutral rating, noting that FQ3 2026 results were in line with expectations and highlighting the positive topline results for brepocitinib.
- Optimistic Market Outlook: With analysts raising sales forecasts for brepocitinib, Roivant Sciences' market outlook is generally positive, showcasing the company's potential and investment value in the biopharmaceutical sector.
See More
Roivant Sciences (ROIV.US) Officer Plans to Sell $5.3 Million in Common Stock via Form 144
Stock Sale Announcement: Officer Venker Eric plans to sell 200,000 shares of its common stock on February 13, with an estimated market value of around $5.3 million.
Reduction in Shareholding: Venker Eric has decreased his shareholding in Roivant Sciences by 682,050 shares since November 20, 2025, totaling an approximate value of $14.88 million.
See More
Top Performing Large-Cap Stocks Last Week
- Lumentum Earnings Beat: Lumentum Holdings Inc. surged 36.02% this week after reporting second-quarter results that exceeded expectations and providing third-quarter guidance above analyst estimates, thereby boosting investor confidence and significantly driving up the stock price.
- Transportation Stocks Rally: Saia, Inc. jumped 23.07% this week, benefiting from declining oil prices, which led to a strong performance across the transportation sector, indicating optimistic market expectations for transportation demand that could enhance future earnings.
- Westlake Stock Increase: Westlake Corporation saw a 19.27% rise in its stock price this week, reflecting positive market sentiment regarding its business outlook, particularly in the context of declining raw material costs that may improve profitability.
- Market Recovery: The strong performance of these stocks indicates a growing investor confidence in economic recovery, especially amid falling oil prices, which could further drive growth in related industries.
See More
